To understand the cause of CCL5-mediated reduced survival in PDAC, we hypothesized that immune cells responsive to a CCL5 chemotactic gradient (through expression of the cognate receptors CCR5, CCR3, or CCR1) could be potential contributors to an adverse tumor immune environment (Figure 1B, Figure 1—figure supplement 1A). This evidence concerns the gene CCR3 and neoplasm.